ClinicalTrials.gg
Sign In

Drug

Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 clinical trials

studies test it
6
open now
4
in phase 3
1
first study started
2022

Keep track of what changes. Save the Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

TQB2868 Injection
4

Development codes

TQB2868
1

Combined with it in one product

TQB2102 with TQB2868
1

Studies by the year they started

6 studies that test it; most in 2022 (2)

Studies that test Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868, by start year
YearStudies
20222
20232
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
4
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Triple Negative Breast Neoplasms
2
Cholangiocarcinoma
1
Neoplasms
1
Uterine Cervical Neoplasms
1

Who runs them

Industry 3 · Other 3

Fudan University (3) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)

Often tested with

Tested in the same studies.

Anlotinib (2) · Trastuzumab rezetecan (2) · Camrelizumab (2) · Famitinib (2) · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 (2) · Bevacizumab (2) · Dalpiciclib (1) · Pyrotinib (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 is read from its arms, and is right about nine times in ten.

Testing it · 6

Given in every arm · 1 — Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 is usual care beside what is tested